About Sofinnova Partners
Sofinnova Partners is a venture capital firm founded in 1972. It is primarily based out of Paris, France. As of Sep 2026, Sofinnova Partners is an active investor, having invested in 167 companies, with 10 new investments in the last 12 months. It primarily invests in Series A round in France based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series B round of EnginZyme Overall, Sofinnova Partners portfolio has seen 26 IPOs and 31 acquisitions including key companies like HOOKIPA Pharma, DBV Technologies and Myricx Bio. A lot of funds co-invest with Sofinnova Partners, with names like Bpifrance sharing a substantial percentage of its portfolio. Sofinnova Partners has team of 48 people including 22 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 5 more
Portfolio Acquisitions
Deals in last 12 months
Sofinnova Partners' List of Top Investments
Sofinnova Partners has a portfolio of 167 companies. Their most notable investments are in RefleXion and Mission Therapeutics.Their portfolio spans across France, United States, United Kingdom and 15 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 17 other sectors, across stages such as Series A, Seed and 5 more. Here is the list of top investments by Sofinnova Partners:1. RefleXion
Provider of biology-guided radiotherapy system. Its patented technology leverages Positron Emission Tomography (PET) which allows tumors to continuously signal their location during treatment and guides personalized radiation therapy. The technology has applications in the treatment of Lung, prostate, and Breast cancers.
Key facts about RefleXion
- Founded Year: 2009
- Location: Hayward (United States)
- Valuation: $*****
- Stage: Series F
- Total Funding till date: $542M
- Employee Count: 123 as on Aug 31, 2026
- Investors: T. Rowe Price, GT Healthcare Capital Partners and 25 Others
- Latest Funding Round: Series F, Nov 13, 2023, $*****
- Highlight: Editors' Pick
Developer of immunotherapies for the treatment of infectious diseases and cancer. The company uses a proprietary arenavirus platform to develop a product pipeline that inlcudes HB-201 and HB-202 for the treatment of Human Papillomavirus-16 positive (HPV16+) cancers.
Key facts about HOOKIPA Pharma
- Founded Year: 2011
- Location: Vienna (Austria)
- Annual Revenue: $10M - $50M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $134M
- Employee Count: 74 as on Apr 27, 2025
- Investors: Redmile Group, Gilead and 12 Others
- Latest Funding Round: Post IPO, Dec 20, 2023, $*****
- Highlight: Public
Developer of products for the treatment of various kinds of food allergies. It is a clinical-stage biopharmaceutical company, engages in the R&D of epicutaneous immunotherapy products. The company provides Diallertest Milk, a diagnostic product for the detection of cow’s milk protein allergy (CMPA) in children. Its products include Viaskin Peanut, an immunotherapy product for the treatment of peanut allergies; Viaskin Milk for the treatment of CMPA and milk-induced eosinophilic esophagitis; and Viaskin Egg, a development program for the treatment of hen’s egg allergy.
Key facts about DBV Technologies
- Founded Year: 2002
- Location: Bagneux (France)
- Annual Revenue: $1M - $10M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $68.9M
- Employee Count: 245 as on Aug 31, 2026
- Investors: Lundbeck Foundation, Eiffel Investment Group and 16 Others
- Latest Funding Round: Post IPO, Apr 07, 2025, $*****
- Highlight: Public
4. TISSIUM
Developer of vascular sealant for open vascular surgery. The company has developed biomorphic and programmable polymers for natural tissue healing. The flagship product, SETALIUM is a biocompatible, biodegradable, and on-demand activated sealant, designed to help achieve hemostasis during open vascular surgery.
Key facts about TISSIUM
- Founded Year: 2013
- Location: Paris (France)
- Stage: Series D
- Total Funding till date: $190M
- Employee Count: 145 as on Aug 31, 2026
- Investors: BNP Paribas, Exor and 17 Others
- Latest Funding Round: Series D, Jun 24, 2026, $*****
- Highlight: Editors' Pick
5. Myricx Bio
Developer of antibody drug conjugates for the treatment of cancer. The company focuses on the development of a pipeline of proprietary differentiated antibody drug conjugates based on novel N-myristoyltransferase inhibitor (NMTi) payload chemistry platform to address serious unmet needs in oncology.
Key facts about Myricx Bio
- Founded Year: 2019
- Location: London (United Kingdom)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $121M
- Investors: Abingworth, Lilly and 13 Others
- Latest Funding Round: Series A, Jul 08, 2024, $*****
- Highlight: Acquired
Sofinnova Partners' Year-on-Year Investment Trends
Sofinnova Partners has invested in 167 companies over the last 28 years, with an average of 10 new investments annually in the last 10 years. In 2025, it made 20 investments, while as of Sep 2026, it has made 12 investments in this year. Its most recent first time investment was in Bionyra and most recent follow-on round was in EnginZyme.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 7 | 5 | 12 |
2025 | 9 | 11 | 20 |
2024 | 6 | 14 | 20 |
2023 | 16 | 13 | 29 |
2022 | 11 | 6 | 17 |
2021 | 13 | 12 | 25 |
2020 | 16 | 8 | 24 |
2019 | 13 | 4 | 17 |
2018 | 9 | 6 | 15 |
2017 | 4 | 3 | 7 |
Sofinnova Partners' Investments by Stage
Sofinnova Partners is primarily an Early Stage Investor investor majorly investing in Series A (83) rounds where average round size is $2.44B, Seed (37) rounds where average round size is $206M and Series C (11) rounds where average round size is $835M.Stage of entry | No. of Investments |
|---|---|
Series A | 83 |
Seed | 37 |
Series C | 11 |
Series B | 9 |
Post IPO | 6 |
Others | 6 |
Note: We have considered here, only first round of investments
Sofinnova Partners' Investments by Sector
Sofinnova Partners has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Sustainability Tech, Enterprise Applications and HealthTech. Notably, it has invested in 146 Tech companies, 135 Enterprise (B2B) companies, 26 Tech hardware companies and at least 17 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 124 |
High Tech | 28 |
Sustainability Tech | 25 |
Enterprise Applications | 12 |
HealthTech | 11 |
Others | 56 |
Note: We have considered here, only first round of investments
Sofinnova Partners' Investments by Geography
Sofinnova Partners has made most investments in France (45), followed by United States where it has made 34 investments.Country | No. of Investments |
|---|---|
France | 45 |
United States | 34 |
United Kingdom | 22 |
Italy | 12 |
Switzerland | 11 |
Others | 27 |
Note: We have considered here, only first round of investments
Sofinnova Partners' recent investments
Sofinnova Partners has made 12 investments in 2026 so far. EnginZyme and HighLife Medical are the latest among them.Here are the most recent investments by Sofinnova Partners:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 24, 2026 | Sweden | Series B | 9808 | [+4] | |
Sep 22, 2026 | France | Series C | 3659 | [+11] | |
Aug 05, 2026 | United Kingdom | Series B | 1112 | [+4] | |
Jun 22, 2026 | France | Series A | 3109 | [+5] | |
Jun 03, 2026 | Poland | Seed | 4674 | [+1] |
IPOs and Publicly Listed companies in Sofinnova Partners' Portfolio
26 of Sofinnova Partners' portfolio companies have become public. Hemab got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in May 2026 at marketcap of $764M and AFYREN got listed on the Euronext Exchange (Euronext) at marketcap of $239M.Here are Sofinnova Partners' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 01, 2026 | Oct 27, 2025 | Series C | 9941 | |
Oct 01, 2021 | Feb 12, 2019 | Series A | 8208 | |
Jul 02, 2021 | Apr 04, 2017 | Series B | 9139 | |
Jun 11, 2020 | - | - | 7300 | |
May 09, 2019 | - | - | 8900 |
Acquired companies in Sofinnova Partners' Portfolio
31 companies from Sofinnova Partners' portfolio have been acquired. The most recent acquisition was Myricx Bio in Jul 2026 by Novartis for $*****.Here are Sofinnova Partners' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 06, 2026 | Oct 28, 2019 | Seed | 7176 | |
Jul 09, 2025 | - | - | 1154 | |
Mar 27, 2025 | May 07, 2020 | Seed | 6776 | |
Apr 05, 2024 | Jan 26, 2014 | Series A | 8369 | |
Mar 14, 2024 | Jan 06, 2023 | Series C | 6727 |
Team profile of Sofinnova Partners
Sofinnova Partners has a team of 48 members including 22 Partners, 3 Venture Partners and 6 Principals located in France, Italy and 7 more locations. Sofinnova Partners' team sits on the board of 1 company.Here is a list of top team members in Sofinnova Partners:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Amsterdam | - | - | |
Partner | London | - | ||
Partner | Milan | - | - | |
Partner | London | - | ||
Partner | Munich | - | - | |
Partner | Madrid | - | ||
Partner | Paris | - | ||
Partner | France | - | - | |
Partner | France | - | - | |
Partner | France | - | ||
Partner | Paris | - |
Co-investors of Sofinnova Partners
Over the past 28 years, 866 investors have co-invested in Sofinnova Partners's portfolio companies. This includes funds and angels.
- Invested before Sofinnova Partners: Europa, HHS and 202 others have invested in rounds before Sofinnova Partners. There are 5 companies where Europa has invested before Sofinnova Partners and 4 companies where HHS has invested before Sofinnova Partners.
- Top Co-investors of Sofinnova Partners: 280 investors entered a company along with Sofinnova Partners. These include investors like Bpifrance (10 companies).
- Invested after Sofinnova Partners: A total of 382 investors have invested in Sofinnova Partners's portfolio after their investments. Top Investors include Bpifrance (11 companies), Europa (11 companies) and EIC Fund (8 companies).
Recent News related to Sofinnova Partners
•
Sofinnova Partners Closes Oversubscribed €82 Million Sofinnova MD Start IV Fund to Create the Next Generation of Medtech CompaniesBusiness Wire•Sep 28, 2026•Sofinnova Partners
•
•
Sofinnova Partners and AWS Team Up to Scale AI Across Life SciencesMedical Product Outsourcing•Aug 24, 2026•Amazon Web Services, Sofinnova Partners, Hoxton Wealth
•
Mironid Secures $46M Series B Funding to Advance Rare Kidney Disease TreatmentGlobeNewswire•Aug 05, 2026•Mironid, BioGeneration Ventures, Epidarex Capital, The Scottish National Investment Bank and 3 others
•
Digital Medicine Pioneer, Deepc, Announces €12 million Series A Round Led by Sofinnova PartnersYahoo•Jul 31, 2026•Deepc AI, Sofinnova Partners
•
•
Novartis strikes $1.5B deal for UK biotech Myricx BioSeeking Alpha•Jul 06, 2026•Novartis, Myricx Bio, Sofinnova Partners, Brandon Capital and 2 others
•
P2 Science has raised $23 Million in new fundingintelligence360•Jun 25, 2026•P2 Science, Sofinnova Partners
•
Bionyra Pharma Secures €143 Million Series A Funding for Biologic MedicinesStartup Rise EU•Jun 23, 2026•Jeito, Sofinnova Partners, Sixty Degree Capital, Vives Fund and 3 others
•
Sofinnova, Sanofi alum unveil Bionyra with $165M and next-gen immunology assetsBioSpace•Jun 22, 2026•Sofinnova Partners, Jeito, Sixty Degree Capital, Vives Fund and 3 others
